Earlier recognition of the exact cause mayhelp clinicians to optimize AKI management in a timely manner, improve clinicaloutcomes such as renal recovery and possibly reduce costs associated withhospital-acquired AKI.4,5This is especially true in patients with clinical syndromes requiring more targetedtherapies than standard AKI supportive care, such as diuretics for cardiorenalsyndromes (CRS), vasopressors plus intravenous albumin for hepatorenal syndromes(HRS) or, more frequently, intravenous fluid therapy for hypovolemic AKI. This evidence concerns the gene ALB and acute kidney injury.